与药物诱导的QT延长相关的药物遗传学标记:系统性审查
Marlene Schouby Bentestuen1,2, Christian Noe Weis3, Caroline Bækmann Jeppesen4
1Psychosis Research Unit, Aarhus University Hospital Psychiatry, Aarhus, Denmark.
Pharmacogenomics
|March 21, 2025
概括
这一系统性审查发现药物诱导的QT间隔延长 (diQTP) 的有限一致的药物基因组学 (PGx) 标志物. 未来的研究需要多样化的群体来进行强大的PGx发现.
科学领域:
- 药物基因组学 药物基因组学
- 心血管药理学心血管药理学
- 临床试验分析
背景情况:
- 遗传变异与药物反应之间的关系,特别是QT间隔变化,对于安全有效的药物治疗至关重要.
- 药物遗传学 (PGx) 标志物可以预测药物的疗效和毒性,但药物诱导的QT间隔延长 (diQTP) 的一致标志物尚未确立.
研究的目的:
- 系统地审查和评估临床研究,评估药物治疗期间患者基因型和QT间隔变化之间的关联.
- 识别和分类涉及diQTP的药物基因组标记,药物类别和生物途径.
主要方法:
- 按照PRISMA指南进行系统审查,并预先注册了一份协议 (CRD42022296097).
- 包括diQTP的PGx标志物的人类临床研究,无论设计,设置,人群或持续时间如何.
- 用ATC代码对基因关联 (药理动力学/药理动力学) 的分类,途径丰富分析和药物分类.
主要成果:
- 84项研究在42种药物类别中发现了213种独特的变异,只有10%的复制;KCNE1-Asp85Asn是最一致的变异.
- 大多数发现 (82%) 来自候选基因研究,表明对已知标记物的潜在偏见.
- 与diQTP相关的基因主要与"心脏导电"和"肌肉收缩"途径有关,与先天性长QT综合征基因发现的重叠.
结论:
- 虽然确定了关键的基因,药物和途径,但观察到diQTP的一致的药物基因组标记物稀缺.
- 广泛的,无偏见的研究,包括多种人群,对于推动药物基因组学研究和临床应用至关重要.
相关概念视频
Pharmacogenetics and Pharmacogenomics: Overview
263
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
263
Principles of Pharmacogenetics: Types of Genetic Variants
143
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenetics of Drug Metabolism: Overview
195
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
195
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
349
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
349
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129


